Effectiveness of Three Dimensional Correction During in Bracing in Adolescent Idiopathic Scoliosis
Launched by THE UNIVERSITY OF HONG KONG · May 7, 2020
Trial Information
Current as of August 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effective a special type of back brace, called the Rigo Chêneau orthosis (RCO), is compared to a more traditional brace known as the Boston-style thoracolumbosacral orthosis (TLSO) in treating adolescents with idiopathic scoliosis, a condition where the spine curves abnormally. The goal is to find out which brace helps correct the spine better and to provide valuable information that can improve treatment for young people with this condition. By doing this study, researchers hope to reduce the need for surgery in these patients, making a positive impact on their health and well-being.
To be eligible for this trial, participants must be between 10 and 15 years old and diagnosed with adolescent idiopathic scoliosis. They should have a specific type of spine curve, measured by what's called a Cobb angle, and not have received any previous treatment for scoliosis, whether surgical or non-surgical. Participants can expect regular follow-ups during the trial to assess how well the braces are working. It's important to note that individuals with certain other medical conditions or who are unable to attend follow-up visits won't be able to join the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of AIS
- • Male or female from 10 to 15 year-old, inclusive, at the time of consent provided
- • Skeletal immaturity, defined as a Risser grade (amount of ossification and eventual fusion of the iliac apophysis) of 0, 1, or 2
- • Cobb angle of 25-40
- • No prior conservative or surgical treatment for AIS
- Exclusion Criteria:
- • An underlying cause or association that may cause scoliosis
- • Leg length discrepancies or lower limb deformities that may interfere with spinal posture
- • Previous spinal surgery
- • Cognitive impairment
- • Those receiving any other forms of treatment including alternative medicine for the treatment of their scoliosis
- • Those who are unable to return for follow-up to complete the trial
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Dr Kenny Kwan, BMBCh (Oxon)
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials